745927
Last Update Posted: 2012-08-14
Recruiting status is unknown
All Genders accepted | 18 Years-80 Years |
400 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Application of CO2 Insufflations in Colonoscopy Randomized Trial
It has been reported that carbon dioxide (CO2) insufflation can reduce patient pain and abdominal discomfort during and after colonoscopy. Its safety and efficacy during colonoscopy even under sedation has been already assessed in some earlier trials. Air insufflation is still the standard method, however, because of a lack of suitable equipment and continued technical improvement in colonoscopy.
In laparoscopic surgery, CO2 insufflation is widely applied and safely used with the patient under general anesthesia. CO2 insufflation is also applied for CT colonography for reduction of discomfort during or after procedure.2 During endoscopic procedure for colorectal neoplasia resection, however, long procedural time may increase not only the degree of discomfort during and after the procedure but also the risk of perforation. In addition to laparoscopic surgery, CO2 insufflation has also been applied to other endoscopic procedures. Saito et al reported the application of CO2 insufflation in Endoscopic submucosal dissection (ESD) of colorectal neoplasia in a prospective study in which their average procedural time using CO2 insufflation was 90 minutes under conscious sedation with average of 5.6 mg of midazolam. When compared with control group using room air, statistically negligible difference of pCO2 was observed with significant difference in abdominal discomfort.6 Screening colonoscopy, which can be completed within 15 minutes if no lesion being detected, requires high screenee satisfaction so as to improve patient compliance. In the setting of colonoscopy after positive FOBT, the attendance rate for secondary colonoscopy was around 60 to 70 % according to the data demonstrated in previous RCT and population-based studies. With application of CO2 insufflation, further improvement of patient compliance can be anticipated.
This study aims to investigate whether use of CO2 insufflations can reduce examinee discomfort in comparison with air.
- Setting: Screening colonoscopy or secondary colonoscopy after positive FOBT performed in endoscopic unit of a single university hospital
- Study design: Single blinded randomized trial
- Randomization process: sealed envelope
- Study subjects:
Inclusion criteria: Subjects who receive Screening colonoscopy or secondary colonoscopy Exclusion criteria: subjects who have COPD or cardiovascular diseases
Study duration: June 2008 to November 2012
Post-colonoscopy discomfort will be measured and obtained from the screenee at several time points using visual analogue pain scoring system:
- Immediately after colonoscopy for non-sedated patients, immediately after awaken from sedation for sedated patients
- 2 hrs after colonoscopy
- 8-12 hours after colonoscopy
Statistical analysis:
- Sample size estimation: according to our previous unpublished data using air insufflations at colonoscopy, mean pain score was 3 and standard deviation was 2.38. Assuming 15% difference of discomfort, sample size up to 171 are required for each group (CO2 vs. air, sedated and non-sedated) in this study. (2 sided test, α=0.05, power=80%)
- Student t-test for pain score comparison
- Ancillary analysis: pCO2, sedation drug dosage, and procedural time in both groups. For TCCO2 comparison, ANOVA for repeated measurement will be used. For variables not normally distributed, Wilcoxon rank sum test wall be used as a supplementary analysis.
- SAS statistical program, version 9.0 (SAS institute Inc., Cary, NC) will be used for all statistical analysis
Eligibility
Relevant conditions:
Colorectal Neoplasm
Colorectal Cancer
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Contact Information
Overall Contact
Han-Mo Chiu, M.D
hanmochiu@ntu.edu.tw
886-2-23123456
Data sourced from ClinicalTrials.gov